AMRX Stock Analysis
AM
Uncovered
Amneal Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 7,600 full-time employees. The company went IPO on 2009-03-16. The firm specializes in developing, manufacturing, marketing and distributing generic and branded specialty pharmaceutical products. The company operates through three segments: Generics, Specialty, and AvKARE. Its Generics segment includes approximately 250 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company operates principally in the United States, India and Ireland.